Paper Review Records
All Paper Review Records
29 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Yi-le Yang; Qi-yue Wang; Yong-qiang Zhou; Xin-ying Zhang; Zhuo-bin Chen; Yong Liu; Yao-hua Hu; Jun-wen Wang; Jing QinShow moreShow less
1. School of Pharmaceutical Sciences, Sun Yat-sen University Shenzhen Campus, Shenzhen, China; 2. School of Pharmacy, Zhejiang University, Hangzhou, China; 3. School of Artificial Intelligence, Guangxi Minzu University, Nanning, China; 4. School of Mathematical Sciences, Shenzhen University, Shenzhen, China; 5. Division of Applied Oral Sciences & Community Dental Care, Faculty of Dentistry, The University of Hong Kong, Hong Kong SAR, ChinaShow moreShow less
IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Yi Ning; Yu Zhou; Qi Zhang; Zhi-wei Chen; Yu-qing Huang; Qi Zhang; Yun Chen; Wen-hao Shi; Qiu-pei Liu; Ya-ping Xue; Tao Zhang; Jian Ding; Wen-hu Duan; Hua XieShow moreShow less
1. Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; 2. University of Chinese Academy of Sciences, Beijing, China; 3. Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China; 4. Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; 5. Department of Chemical and Environmental Engineering, Science and Engineering Building, The University of Nottingham Ningbo China, Ningbo, ChinaShow moreShow less
Structure-based virtual screening with AlphaFold identifies CLIP1-LTK inhibitors
Wang-lin Qu; Xu-jun Zhang; Gao-ang Wang; Wei-xin Tian; Kang Chen; Yuan-yi Ye; Shi-cheng Chen; Ru-bi Hu; Yi-fei Liu; Chao Shen; Dan Li; Yu Kang; Sheng Tian; Peng Teng; Ting-jun Hou; Pei-chen PanShow moreShow less
1. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China; 2. Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; 3. College of Pharmaceutical Sciences, Soochow University, Suzhou, China; 4. Zhejiang Key Laboratory of Intelligent Drug Discovery and Development, Jinhua Institute of Zhejiang University, Jinhua, ChinaShow moreShow less
Hesperetin ameliorates APAP-induced liver injury by activating a PKC–TFEB axis
Shu-jun Chen; Yi-xin Chen; Yu-jie Zhao; Jing-min Zeng; Shi-yun Tan; Hao Wang; Li-rong Wang; Xiao-juan Chao; Shao-gui WangShow moreShow less
1. State Key Laboratory of Traditional Chinese Medicine Syndrome, Chinese Medicine Guangdong Laboratory (Hengqin Laboratory), International Institute for Translational Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China; 2. Key Laboratory of Chinese Medicinal Resource from Lingnan (Guangzhou University of Chinese Medicine), Ministry of Education, Guangzhou, China; 3. Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China; 4. Department of Gastroenterology and Hepatology, Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; 5. Dongguan Institute of Guangzhou University of Chinese Medicine, Dongguan, ChinaShow moreShow less
Anticancer drug discovery: Embracing the next wave of innovation
Min Huang; Mei-yu Geng; Jian DingShow moreShow less
1. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; 2. University of Chinese Academy of Sciences, Beijing, ChinaShow moreShow less
Inhibition of histone deacetylase 3 alleviates lithocholic acid-induced intrahepatic cholestasis by enhancing expression of bile acid and lipid homeostasis-related genes
Jing-shu Li; Xiao-wen Jiang; Pei-bin Chen; Xuan Li; Xiao Yang; Shi-cheng Fan; Yue Gao; Jian-hong Fang; Feng Qiu; Hui-chang BiShow moreShow less
1. Department of Laboratory Medicine, The Seventh Affiliated Hospital, Southern Medical University, Foshan, China; 2. State Key Laboratory of Multi-organ Injury Prevention and Treatment, Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, Key Laboratory of Mental Health of the Ministry of Education, Guangdong Basic Research Center of Excellence for Integrated Traditional and Western Medicine for Qingzhi Diseases, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, ChinaShow moreShow less
FAQ
How long does ACTA PHARMACOLOGICA SINICA take to review a manuscript?
As of 2026-11-18, CrushSCI has 29 complete review records for ACTA PHARMACOLOGICA SINICA. The fastest paper went from submission to acceptance in 1 days (Anticancer drug discovery: Embracing the next wave of innovation, received 2026-09-29, accepted 2026-09-30); the slowest took 235 days. The average is 131 days and the median is 125 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
